Cytokinetics (CYTK) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $80.01 +1.06%
Revenue Growth %: -75.4%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -75.4%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($0.60), $0.03 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $8.33 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
